Levelling the SPC playing field

“The EU’s highest court, in a 2013 ruling, held it is possible for a product to be classified as a medical device in one EU member state and a medicine in another.”

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Pharma

Beyond the primary patent: How pharma can build competitive barriers

16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

More features

Beyond the primary patent: How pharma can build competitive barriers

Patent lawyers and judges discuss lofty UPC issues in grand London venue

Teva faces scrutiny over efforts to curb generic competition

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UPC upholds injunction in Invisalign maker’s software dispute with rival

EU court under pressure to define SPC limits in patent row

Levelling the SPC playing field

More on this story

Editor's picks

Editor's picks

More features